Home >> Top News >> Binding Site varicella zoster virus antigens

Binding Site varicella zoster virus antigens

Print Friendly, PDF & Email

Oct. 2, 2017Binding Site’s Immunologicals Group has added two varicella zoster virus antigens to its line of products for in vitro diagnostic manufacturing and research applications. Both the standard VZV antigen and the VZV glycoprotein antigen have been expressly designed for use as integral components within solid phase enzyme immunoassay test procedures and to benefit the needs of biopharmaceutical, clinical, drug-discovery, and life science researchers, as well as manufacturers of IVD test kits.

Both VZV antigens exhibit exceptional purity levels as a result of chromatography techniques and demonstrate exceptional lot-to-lot consistencies while displaying the highest degrees of activity and specificity, according to the company. Shelf life stability is 10 years from the date of manufacture. The antigens are offered in a standard size 1.0-mg filled vial; larger, bulk configurations are also available.

More top news


Check Also

IgG subclass antibodies

June 2018—Binding Site’s Immunologicals Group announced the availability of affinity-purified, unconjugated, anti-human antibodies to the IgG subclasses, including IgG1, IgG2, IgG3, and IgG4, for IVD research use in solid phase enzyme immunoassay based test methods, especially ELISAs, and other potential testing applications.